Abstract: Compounds of a certain formula (I), in which R1, R2, R3, R4, R5, R6 and R7 have the meanings indicated in the description, are novel effective HDAC inhibitors.

Abstract: Compounds of a certain formula I, in which R1, R2, R3, R4 and X have the meanings indicated in the description, are novel effective compounds with Eg5 inhibitory, anti-proliferative and/or apoptosis inducing activity.

Abstract: The compounds of Formula (I) in which R1, R2, R3 and R4 have the meanings as given in the description are novel effective iNOS inhibitors.

Abstract: The compounds of formula (I) In which R1, R2, R3, R4, R5 and A have the meanings as given in the description are novel effective iNOS inhibitors.

Abstract: The compounds of Formula (I) in which R1, R2, R3 and R4 have the meanings as given in the description are novel effective iNOS inhibitors.

Abstract: The compounds of formula (I) in which R1, R2, R3, R4, R5 and A have the meanings as given in the description are novel effective iNOS inhibitors.

Abstract: The compounds of formula I in which R1, R2, R3, R4 and R5 have the meanings as given in the description are novel effective antiinflammatory compounds.

Abstract: Compounds of a certain formula (I), in which Ra and Rb have the meanings indicated in the description, are novel effective compounds with anti-proliferative and apoptosis inducing activity.

Abstract: The compounds of Formula (I) in which R1, R2, R3, R4, R5 and A have the meanings as given in the description are novel effective iNOS inhibitors.

Abstract: The compounds of formula I in which R1, R2, R3, R4, R5, R6 and n have the meanings as indicated in the description, are novel effective PDE3/4 inhibitors.

Abstract: The compounds of formula I in which R1 and R2 have the meanings as given in the description are novel effective PDE2 inhibitors.

Abstract: The compounds of Formula (I) in which R1, R2, R3, R4, R5 and A have the meanings as given in the description are novel effective iNOS inhibitors.

Abstract: Compounds of a certain formula 1 in which R1 and R2 have the meanings indicated in the description are novel kinase inhibitors. Formula (1), in which R1 is phenyl, phenyl substituted by R3 and/or R4, naphthalenyl, naphthalenyl substituted by and/or R6, aryl1, aryl1 substituted by R7 and/or R8, R9, R10 or R11, R2 is phenyl, phenyl substituted by R12 and/or R13, naphthalenyl, naphthalenyl substituted by R14 and/or R15, aryl2, aryl2 substituted by R16 and/or R17 or a radical selected from Formula (2).

Abstract: The invention relates to pantoprazole and (S)-pantoprazole salts and to medicaments comprising these compounds.

Abstract: The compounds of a certain formula (1), in which R1, R2, R3 and R9 have the meanings as given in the description, are novel effective PDE4 inhibitors.

Abstract: To provide an access route which is leaktight and at the same time permits mobility and exact positioning of an instillation catheter (6), an arrangement comprising an instillation catheter (6) and a connector piece (1) for attachment to a tracheal or endotracheal tube is proposed. The connector piece (1) has a distal end (1a) for attachment to the tube, and a proximal end (1b) for attachment to a ventilation and/or suction device and comprises a branch (5) which serves for insertion of the catheter (6) and in which a valve (2) is arranged. The valve (2) is made, at least in some areas, from an elastically deformable material and can be opened by insertion of the catheter (6). The valve further comprises a proximal through-opening (21) whose inner wall has a means allowing sealing against axial flow of fluid between catheter (6) and inner wall, and, in the distal direction from the through-opening, it has a beak section (22) which, at its beak tip (23), has a normally closed slit (24).

Abstract: Compounds of a certain formula I in which R1, R2, R3, R31, R4, R5, R51 and Har have the meanings indicated in the description, are novel effective PDE4 inhibitors.

Abstract: Compounds of the formula I in which the substituents have the definitions provided in the specification, are novel, effective PDE4 inhibitors.

Abstract: The invention relates to novel pyrrolodihydroisoquinoline derivatives, which are efficacious inhibitors of PDE10.

Abstract: Compounds of the formula I in which the substituents have the definitions provided in the specification, are novel, effective PDE4 inhibitors.